G protein-coupled receptors (GPCRs), crucial for diverse physiological responses, have traditionally been investigated in ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Tectonic Therapeutic, Inc. has seen a significant stock rally which has seen its shares nearly triple since this summer. What ...

Certa Therapeutics Pty Ltd. has acquired Occurx Pty Ltd. in a move to strengthen its pipeline to target multiple fibrotic diseases as both companies share a focus on targeting GPR68, a defined G ...

Kaken will take the drug through phase I trials, after which J&J takes over. Under the terms, Kaken banks an up-front payment of $30 million and could collect more than $1.2 billion if development and ...

Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with ...

Exicure, Inc. , has announced the signing of a Memorandum of Understanding (MOU) with GPCR Therapeutics, Inc. ("GPCR Therapeutics") on December 24, 2024, aimed at the acquisition of GPCR USA, a ...

Breast cancer remains a leading health crisis worldwide, claiming the lives of approximately 685,000 women in 2020 alone.

Fintel reports that on December 23, 2024, D. Boral Capital initiated coverage of Omeros (NasdaqGM:OMER) with a Buy ...

Dis new pathway go allow migrants and dia families to come live permanently for Australia. Di National Innovation visa dey replace di Global Talent visa wey end for 6 December. According to di ...

Almost 35% of drugs approved by the Food and Drug Administration work by targeting G protein-coupled receptors (GPCRs), proteins embedded in cell membranes that allow cells to communicate with ...